Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Leukemia

FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

Benzinga

Going For Gold: Metal Detector Couple Find Five Rare 14th Century Gold Coins In Field

A metal detectorist couple unearthed five rare 14th-century gold coins from the reign of Edward III in a field that could fetch up to £15,000 – and the find happened while one of them was suffering from leukemia.

Zenger

Glasgow dad opens up as gymnast daughter's 'growing pains' lead to cancer diagnosis

Liv Dickson's determination to beat the disease has inspired her dad Allan to taken on a massive charity effort to raise money to help develop new treatments, and he will cycle the 3,500km Tour de France route next month.

Glasgow Live

From analysis to the latest developments in health,
read the most diverse news in one place.

The youngest of the 10 people killed in the Buffalo shooting was laid to rest

Roberta Drury grew up in the Syracuse area and moved to Buffalo a decade ago to help tend to her brother in his fight against leukemia. She was remembered for her love for family and friends.

WEKU

FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ:FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The FDA initiated the partial clinical hold following the report of a recent death that occurred in a subject with potential differentiation syndrome. Differentiation…

Benzinga

Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial

Magenta Therapeutics Inc (NASDAQ:MGTA) shared preliminary data from the Phase 1/2 dose-escalation trial of MGTA-117 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts. The data comes from a Cohort 1, evaluating the lowest dose of MGTA-117 (0.02 mg/kg). Three patients completed the safety evaluation period. A fourth patient with…

Benzinga

Nottingham couple forced to raise funds to treat daughter abroad

"Its pretty horrific all the time but the hope that this might be her cure is getting us through"

Nottingham Post

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

More Australians dying of myeloma, a blood cancer that causes bones to weaken

Each day six Australians are diagnosed with myeloma, a rare form of blood cancer that weakens bones, and about half of those people won't survive past five years.

ABC News

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

$FDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation$

FDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

Aptose Biosciences Inc. (NASDAQ: APTO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation.

Benzinga

Jasper Therapeutics Presented Updated Data from Phase 1 Clinical Trial of JSP191

Jasper Therapeutics, Inc., (NASDAQ: JSPR) announced updated efficacy, safety and pharmacokinetic data from its Phase 1 clinical trial of JSP191, in older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic (blood) cell transplantation.

Benzinga

Gary Lineker opens up on son George's leukaemia battle and "tiny coffin" nightmare

Gary Lineker has opened up his son's harrowing battle with leukaemia as an infant - revealing that he had nightmares of carrying a "tiny little white coffin" during George's ordeal

Daily Mirror

Mustang Bio's CAR T Cell Therapy Shows Favorable Safety Profile, Response Rates In Blood Cancer Patients

Mustang Bio Inc (NASDAQ:MBIO) announced updated interim data from the ongoing Phase 1/2 trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center. The data demonstrated…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

1 … 3 4 5 6

People

Gary Lineker

2,443 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Ginkgo Bioworks Holdings Inc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.